Key Points {#FPar1}
==========

In a post hoc analysis of four clinical pharmacology trials in subjects with type 1 diabetes mellitus, it was shown that faster aspart provides accelerated pharmacokinetics compared with insulin aspart (IAsp) independent of whether free or total insulin is assayed.Higher anti-IAsp antibody levels were associated with greater exposure for total versus free insulin---both in the clinical pharmacology trials and based on sparse pharmacokinetic sampling in a phase IIIa trial with faster aspart and IAsp.Presence of anti-IAsp antibodies does not appear to affect the greater early glucose-lowering effect provided by faster aspart versus IAsp, nor does the level of anti-IAsp antibodies appear to influence the overall glucose-lowering effect of faster aspart and IAsp.

Introduction {#Sec1}
============

In insulin-treated patients with diabetes, insulin may exist in the circulation both as bound and free insulin. The bound fraction is due to reversible binding to endogenous anti-insulin antibodies \[[@CR1], [@CR2]\]. Recently, anti-insulin antibodies have received less attention because of reduced impurities of insulin products and widespread use of human insulin and human-derived insulin analogues. Still, therapeutic insulins continue to be immunogenic in many patients \[[@CR3]--[@CR5]\]. Consequently, interference by anti-insulin antibodies in insulin assays remains an important issue \[[@CR6]\]. In contrast to direct measurement of total insulin (bound plus unbound), determination of free insulin concentrations requires prior removal of anti-insulin antibodies before analysis, a step accomplished by polyethylene glycol precipitation \[[@CR1], [@CR2]\]. In the past, pharmacokinetic characterisation of exogenous insulin products in previously insulin-treated subjects was based on measurement of either total insulin \[[@CR7], [@CR8]\] or free insulin \[[@CR9]--[@CR11]\].

Fast-acting insulin aspart (faster aspart) has been developed as an ultra-fast-acting formulation of the mealtime insulin, insulin aspart (IAsp) \[[@CR12], [@CR13]\]. Faster aspart contains two additional excipients, [l]{.smallcaps}-arginine and niacinamide, to facilitate formulation stability and faster initial absorption \[[@CR14], [@CR15]\]. Importantly, the IAsp molecule in faster aspart is unmodified compared with the original IAsp formulation. Based on free IAsp measurements in subjects with type 1 diabetes mellitus (T1DM), faster aspart provides \~ 5 min earlier onset of appearance and twice-as-high early insulin exposure in the first 30 min post-dosing compared with IAsp \[[@CR16]\]. However, it may also be relevant and has been requested by some regulatory authorities to compare the pharmacokinetics of faster aspart and IAsp based on total IAsp measurements. Such an investigation was possible because both free and total IAsp were measured in selected trials in the faster aspart clinical development programme.

Thus, the main purpose of the current investigation was to compare the pharmacokinetics between faster aspart and IAsp based on both total and free IAsp measurements in subjects with T1DM. This was done in a post hoc analysis of the four clinical pharmacology trials in the faster aspart clinical development programme where both free and total IAsp measurements were available. Furthermore, the influence of anti-IAsp antibody levels on the exposure and glucose-lowering effect of faster aspart and IAsp was explored. The analysis was supplemented with pharmacokinetic and meal test results from a large phase IIIa trial with faster aspart and IAsp.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

The current post hoc analysis included four clinical pharmacology trials contributing pharmacokinetic and anti-IAsp antibody data (Trials 1--4) (Electronic Supplementary Material \[ESM\] Online Resource 1, Table S1). Three of these trials used a glucose clamp and therefore also contributed pharmacodynamic data (Trials 1--3). All four clinical pharmacology trials were randomised, double-blind, crossover trials and were conducted at Profil, Neuss, Germany (Trials 1 and 2) \[[@CR15], [@CR17]\], SOUSEIKAI, Hakata Clinic, Fukuoka, Japan (Trial 3) \[[@CR18]\] and Department of Internal Medicine, Medical University of Graz, Austria (Trial 4) \[[@CR19]\]. Independent of trial centre, the clinical pharmacology trials used comparable overall methodology and had a similar design including IAsp as comparator. It was therefore assessed valid to pool the four trials in a combined analysis. For the investigation of the association between anti-IAsp antibody levels and exposure as well as the glucose-lowering effect of faster aspart and IAsp, the clinical pharmacology data were supplemented with data from a phase IIIa multicentre, active-controlled, randomised, parallel-group trial with faster aspart and IAsp in subjects with T1DM (Trial 5) \[[@CR20]\].

In each trial, health authorities and local ethics committees reviewed and approved the protocol, protocol amendments, consent form and subject information sheets according to local regulations prior to trial initiation. All trials were performed in accordance with the Declaration of Helsinki and Good Clinical Practice. Participants provided written informed consent before initiation of any trial-related activities. The trials were registered at ClinicalTrials.gov: NCT01618188 (Trial 1), NCT02003677 (Trial 2), NCT01934712 (Trial 3), NCT02568280 (Trial 4) and NCT01831765 (Trial 5).

Study Populations {#Sec4}
-----------------

The combined analysis of clinical pharmacology trials was based on data from 175 adults with T1DM aged ≥ 18 years. The analysis of data from the phase IIIa trial included 1040 adults with T1DM aged ≥ 18 years. For all trials, only subjects with available pharmacokinetic data for both free and total IAsp as well as data on anti-IAsp antibodies were included in the current analysis.

Key inclusion criteria for each trial are shown in ESM Online Resource 1, Table S1. In the clinical pharmacology trials, subjects had received treatment with multiple daily insulin injections or insulin pump therapy for ≥ 12 months with total insulin dose \< 1.2 (I)U/kg/day and bolus insulin dose \< 0.7 (I)U/kg/day. In the phase IIIa trial, subjects had been treated in a basal-bolus insulin treatment regimen for ≥ 12 months and with insulin detemir or insulin glargine as basal insulin for ≥ 4 months. General exclusion criteria in the clinical pharmacology trials included clinically significant concomitant diseases (malignant neoplasms or cardiovascular, renal, hepatic, respiratory, gastrointestinal or haematological diseases), history of severe allergies to medication or foods or a history of severe anaphylactic reaction, smoking (not in Trial 4) or current treatment with drug(s) that might interfere with glucose metabolism. Exclusion criteria in the phase IIIa trial included any use of anti-diabetes drugs other than insulin ≤ 3 months prior to screening, known or suspected hypersensitivity to any of the trial products or related products, recurrent severe hypoglycaemia, hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis ≤ 6 months prior to screening. Pregnant or breastfeeding women were excluded from all trials.

Study Procedures and Assessments {#Sec5}
--------------------------------

In all four clinical pharmacology trials, subjects received single subcutaneous dosing of faster aspart (100 U/mL; Novo Nordisk, Bagsværd, Denmark) and IAsp (NovoRapid^®^; 100 U/mL; Novo Nordisk) into a lifted skin fold of the lower abdominal wall above the inguinal area. In Trial 1, subjects received two formulations of faster aspart, but the current analysis included only data for the formulation pursued in further clinical development. In Trials 1--3, the dose was fixed at 0.2 U/kg, while subjects in Trial 4 received an individualised dose of 0.06--0.28 U/kg (identical at both dosing visits for each subject) based on the subject's customary insulin:carbohydrate ratio. The two dosing visits were separated by at least 3 days' washout, where subjects resumed their usual insulin treatment. Blood samples for serum IAsp measurement were drawn at pre-specified timepoints shown in ESM Online Resource 1, Table S2.

In Trials 1, 2 and 3, which contributed pharmacodynamic data, an automated euglycaemic glucose clamp (Biostator^®^, MTB Medizintechnik, Amstetten, Germany in Trial 1; ClampArt^®^, Profil, Neuss, Germany in Trial 2; STG-22 Artificial Endocrine Pancreas, NIKKISO Co. Ltd., Tokyo, Japan in Trial 3) with a target blood glucose concentration of 5.5 mmol/L (100 mg/dL) was performed up to 12 h post-dosing. Clamp procedure details have been provided previously \[[@CR15], [@CR18]\]. In Trial 4, a 6-h mixed meal test was conducted and postprandial glucose turnover was assessed by the triple-tracer method (data published previously \[[@CR19]\]).

In the clinical pharmacology trials, the subjects' current insulin therapy was washed out before each trial product administration. Subjects were not allowed to take insulin degludec ≤ 72 h pre-dose, insulin glargine or insulin detemir ≤ 48 h pre-dose, intermediate-acting insulin (e.g. neutral protamine Hagedorn \[NPH\] insulin) ≤ 22 h pre-dose or IAsp ≤ 12 h (for bolus) or ≤ 8 h (for basal infusion using a pump) pre-dose.

In the phase IIIa trial, subjects were randomised to receive 26 weeks' treatment with double-blind mealtime faster aspart, mealtime IAsp or open-label post-meal faster aspart in a basal-bolus regimen with insulin detemir as basal insulin. Mealtime bolus insulin was injected 0--2 min pre-meal, while post-meal faster aspart was injected 20 min after the start of a meal. At 26 weeks of treatment, in connection with a standardised liquid meal test, a fixed dose of 0.1 U/kg was administered 0--2 min pre-meal (mealtime faster aspart and IAsp) or 20 min after the start of a meal (post-meal faster aspart). Blood sampling for anti-IAsp antibody measurement was done before the meal test, while blood sampling for pharmacokinetic assessment was done at 1 and 2 h after the start of meal ingestion. Plasma glucose was measured immediately pre-meal and every hour until 4 h post-meal. Subjects were required to attend the meal test fasting and abstain from any insulin injection, and medication to be taken during or after a meal, until the meal test was completed.

Free and total serum IAsp concentrations were measured using a validated IAsp-specific enzyme-linked immunosorbent assay with a lower limit of quantification of 10 pmol/L. Before measurement of free IAsp, serum samples were precipitated using polyethylene glycol to obtain a supernatant fraction containing free IAsp.

Total anti-IAsp antibodies (IAsp-specific antibodies as well as those cross-reacting with human insulin) were measured by a validated subtraction radioimmunoassay using ^125^I-labelled IAsp. Serum samples were incubated with ^125^I-labelled IAsp in the presence or absence of unlabelled antigen (IAsp or human insulin). Radiolabelled IAsp bound to antibodies in the sample was precipitated, measured and expressed as percent bound radioactivity (B) of the total amount of radioactivity (T) added to the sample. Thus, the %B/T value is proportional to the amount of anti-IAsp antibody present in the sample. Since the assay is a subtraction radioimmunoassay, where the assay background is subtracted, %B/T varies around zero for antibody-negative samples due to assay variation. Thus, %B/T may be slightly below zero for antibody-negative samples.

Study Endpoints {#Sec6}
---------------

In the clinical pharmacology trials, onset of exposure was assessed by the endpoints onset of appearance, time to 50% of maximum IAsp concentration in the early part of the pharmacokinetic profile (*t*~Early 50 % *C*max~) and time to maximum IAsp concentration (*t*~max~). Early IAsp exposure was evaluated by the areas under the concentration--time curve (AUCs) for serum IAsp from time zero to 15 (AUC~IAsp,0--15 min~), 30 (AUC~IAsp,0--30 min~) and 60 min (AUC~IAsp,0--60 min~), respectively. Offset of IAsp exposure was assessed by the time to 50% of maximum IAsp concentration in the late part of the pharmacokinetic profile (*t*~Late 50 % *C*max~) and the AUC for serum IAsp from 2 h (AUC~IAsp,2--*t*~). Overall IAsp exposure was evaluated by total AUC for serum IAsp (AUC~IAsp,0--*t*~) and maximum IAsp concentration (*C*~max,IAsp~). Early glucose-lowering effect was assessed by the AUC for the glucose infusion rate (GIR) from time zero to 60 min (AUC~GIR,0--60 min~), offset of glucose-lowering effect was evaluated by the AUC for the GIR from 2 h (AUC~GIR,2--*t*~) and overall glucose-lowering effect was assessed by the total GIR (total AUC for GIR \[AUC~GIR,0--*t*~\]). All endpoints were calculated as previously described \[[@CR16]\].

In the phase IIIa trial (Trial 5), AUC~IAsp,0--*t*~ was predicted from the two IAsp concentration measurements performed post-dose at 26 weeks of treatment. The prediction was based on data from available clinical pharmacology trials with faster aspart and IAsp (described in ESM Online Resource 1). Moreover, the 1-h postprandial plasma glucose increment (ΔPPG~1h~) of the meal test was calculated.

Statistical Analyses {#Sec7}
--------------------

All statistical analyses were performed using SAS^®^ version 9.4 (SAS Institute, Cary, NC, USA). Pharmacokinetic endpoints from the clinical pharmacology trials were compared between faster aspart and IAsp in a linear mixed model with treatment and trial as fixed effects and subject as random effect. Onset of appearance, *t*~Early 50 % *C*max~, *t*~max~ and *t*~Late 50 % *C*max~ were analysed on an absolute scale: least square means for each treatment as well as treatment differences and 95% confidence intervals (CIs) were estimated. All AUCs for serum IAsp and *C*~max,IAsp~ were log-transformed before analysis, and least square means for each treatment as well as treatment ratios and 95% CIs were estimated.

The potential effect of anti-IAsp antibodies on the exposure of free and total IAsp was investigated by plotting the relationship between the level of anti-IAsp antibodies and the ratio of measured exposure of free versus total IAsp. Plots were prepared for the combined clinical pharmacology trials and for the phase IIIa trial. Only those subjects with available data for anti-IAsp antibody level and AUC~IAsp,0--*t*~ for both free and total IAsp (for faster aspart and/or IAsp) were included in the plot.

Based on the clinical pharmacology trials, the potential effect of anti-IAsp antibodies on the early glucose-lowering effect and on the offset of glucose-lowering effect of faster aspart versus IAsp was investigated by calculating the mean ratio of faster aspart/IAsp for AUC~GIR,0--60 min~ and AUC~GIR,2--*t*~ for each of four subgroups ranging from the lowest to the highest level of anti-IAsp antibodies. In addition, the potential effect of anti-IAsp antibodies on overall glucose-lowering effect of faster aspart and IAsp was investigated by plotting the relationship between level of anti-IAsp antibodies and AUC~GIR,0--*t*~. Finally, based on the mealtime faster aspart and IAsp treatment arms in the phase IIIa trial, the potential effect of anti-IAsp antibodies on 1-h postprandial glucose increment in a meal test was investigated by plotting the relationship between the level of anti-IAsp antibodies and ΔPPG~1 h~ for both faster aspart and IAsp.

Results {#Sec8}
=======

Subjects {#Sec9}
--------

A total of 175 subjects from the four clinical pharmacology trials were administered both faster aspart and IAsp and contributed to the pharmacokinetic analysis. In 112 subjects from three of the clinical pharmacology trials, pharmacodynamic glucose clamp data were available and included in the pharmacodynamic analysis. Analysis of the phase IIIa trial included the 1040 subjects with available pharmacokinetic data for both free and total IAsp and an anti-IAsp antibody measurement at 26 weeks of treatment. A total of 347, 341 and 352 subjects received mealtime faster aspart, post-meal faster aspart and mealtime IAsp, respectively. Baseline characteristics for both clinical pharmacology trial populations and for the phase IIIa trial population are summarised in ESM Online Resource 1, Table S3. In the pooled population from the clinical pharmacology trials, the majority of subjects were male (65%), and subjects had a mean age of 42 years (range 21−73 years), body weight of 72.0 kg (range 48.6--100.0 kg), body mass index (BMI) of 23.9 kg/m^2^ (range 18.5−28.7 kg/m^2^), duration of diabetes of 21 years (range 1−57 years), glycosylated haemoglobin (HbA~1c~) at baseline of 7.3% (52 mmol/mol) (range 5.2−9.2%; 30−71 mmol/mol) and an anti-IAsp antibody level at baseline of 10.8%B/T (range − 0.1 to 66.9%B/T). The subset included in the pharmacodynamic analysis had comparable baseline characteristics. In the phase IIIa trial population, the majority of subjects were male (59%), and subjects had a mean age of 45 years (range 18−83 years), body weight of 80.0 kg (range 45.3−140.0 kg), BMI of 26.7 kg/m^2^ (range 17.0−37.9 kg/m^2^), duration of diabetes of 20 years (range 1--65 years), HbA~1c~ at baseline of 7.6% (59 mmol/mol) (range 5.6−9.8%; 38--84 mmol/mol) and an anti-IAsp antibody level at 26 weeks of treatment of 18.0%B/T (range 0.2−86.7%B/T).

Pharmacokinetics of Faster Aspart Versus Insulin Aspart (IAsp) for Free and Total IAsp {#Sec10}
--------------------------------------------------------------------------------------

Comparisons of mean serum IAsp concentration--time curves between faster aspart and IAsp are shown for both free and total IAsp in Fig. [1](#Fig1){ref-type="fig"}. As expected, total IAsp concentrations were higher than free IAsp concentrations irrespective of insulin product. But importantly, a similar left-shift of the serum IAsp concentration--time curve was seen with faster aspart versus IAsp independent of whether pharmacokinetics were measured as free or total IAsp.Fig. 1Mean serum IAsp concentration--time profiles after subcutaneous faster aspart or IAsp administration in subjects with type 1 diabetes mellitus when using an assay to measure free IAsp (**a**, **c**) or total IAsp (**b**, **d**). 5-h profiles are shown in **a**, **b**, while 2-h profiles are shown in **c**, **d**. Mean pharmacokinetic profiles are based on 175 individual profiles per treatment. The dose was adjusted to 0.2 U/kg in all subjects. Variability bands show the standard error of the mean. *IAsp* insulin aspart

As seen in Table [1](#Tab1){ref-type="table"}, onset of appearance occurred earlier and *t*~Early 50 % *C*max~ and *t*~max~ were shorter for faster aspart than IAsp both for free and total IAsp. Furthermore, the quantitative differences between faster aspart and IAsp for onset of appearance, *t*~Early 50 % *C*max~ and *t*~max~ were comparable for free and total IAsp (Table [1](#Tab1){ref-type="table"} and ESM Online Resource 1, Table S4).Table 1Onset of exposure for faster aspart versus insulin aspart after subcutaneous administration in subjects with type 1 diabetes mellitus when using an assay to measure free or total insulin aspartVariableFree IAspTotal IAspTreatment difference (faster aspart − IAsp)\
\[95% CI\]*p* value^a^Treatment difference (faster aspart − IAsp)\
\[95% CI\]*p* value^a^Onset of appearance (min)− 4.1 \[− 4.7 to − 3.6\]\< 0.001− 2.5 \[− 2.8 to − 2.1\]\< 0.001*t*~Early 50 % *C*max~ (min)^b^− 8.8 \[− 10.0 to − 7.5\]\< 0.001− 7.6 \[− 8.8 to − 6.4\]\< 0.001*t*~max~ (min)− 10.8 \[− 15.4 to − 6.3\]\< 0.001− 10.6 \[− 14.7 to − 6.5\]\< 0.001Results are based on 175 individual pharmacokinetic profiles per treatment*CI* confidence interval, *IAsp* insulin aspart, *t*~*Early* *50* *%* *Cmax*~ time to 50% of maximum IAsp concentration in the early part of the pharmacokinetic profile, *t*~*max*~ time to maximum IAsp concentration^a^For treatment comparison of faster aspart vs. IAsp^b^Not determined in Trial 4

Greater early exposure up to 60 min after dosing was seen with faster aspart than with IAsp irrespective of pharmacokinetic assay method, and the quantitative differences between faster aspart and IAsp for early exposure were in the same range for free and total IAsp (Table [2](#Tab2){ref-type="table"} and ESM Online Resource 1, Table S5). For example, AUC~IAsp,0--30 min~ was close to twice-as-great with faster aspart versus IAsp for both free and total IAsp (treatment ratios for faster aspart/IAsp of 1.88 and 1.77, respectively).Table 2Early exposure for faster aspart versus insulin aspart after subcutaneous administration in subjects with type 1 diabetes mellitus when using an assay to measure free or total insulin aspartVariableFree IAspTotal IAspTreatment ratio (faster aspart/IAsp)\
\[95% CI\]*p* value^a^Treatment ratio (faster aspart/IAsp)\
\[95% CI\]*p* value^a^AUC~IAsp,0--15 min~ (pmol·h/L)3.40 \[3.00--3.85\]\< 0.0012.87 \[2.58--3.20\]\< 0.001AUC~IAsp,0--30 min~ (pmol·h/L)1.88 \[1.74--2.04\]\< 0.0011.77 \[1.64--1.90\]\< 0.001AUC~IAsp,0--60 min~ (pmol·h/L)1.29 \[1.22--1.36\]\< 0.0011.26 \[1.20--1.33\]\< 0.001Results are based on 175 individual pharmacokinetic profiles per treatment. The dose was adjusted to 0.2 U/kg in all subjects*AUC*~*IAsp,0*-x *min*~ area under the concentration--time curve for IAsp from time zero to *x* min, *CI* confidence interval, *IAsp* insulin aspart^a^For treatment comparison of faster aspart vs. IAsp

The offset of IAsp exposure occurred earlier for faster aspart than for IAsp independent of assay method. Moreover, the relative differences between faster aspart and IAsp for *t*~Late 50 % *C*max~ and AUC~IAsp,2--*t*~ were comparable for free and total IAsp (Table [3](#Tab3){ref-type="table"} and ESM Online Resource 1, Table S6).Table 3Offset of exposure for faster aspart versus insulin aspart after subcutaneous administration in subjects with type 1 diabetes mellitus when using an assay to measure free or total insulin aspartVariableFree IAspTotal IAspTreatment difference (faster aspart − IAsp)\
\[95% CI\]*p* value^a^Treatment difference (faster aspart − IAsp)\
\[95% CI\]*p* value^a^*t*~Late 50 % *C*max~ (min)− 13.8 \[− 20.0 to − 7.6\]\< 0.001− 14.0 \[− 20.1 to − 7.9\]\< 0.001VariableFree IAspTotal IAspTreatment ratio (faster aspart/IAsp)\
\[95% CI\]*p* value^a^Treatment ratio (faster aspart/IAsp)\
\[95% CI\]*p* value^a^AUC~IAsp,2--*t*~ (pmol·h/L)0.88 \[0.81--0.96\]0.0050.89 \[0.84--0.96\]0.001Results are based on 175 individual pharmacokinetic profiles per treatment. For AUC~IAsp,2--*t*~, the dose was adjusted to 0.2 U/kg in all subjects*AUC*~*IAsp,2*--*t*~ area under the concentration--time curve for IAsp from 2 h, *CI* confidence interval, *IAsp* insulin aspart; *t*~*Late* *50* *%* *Cmax*~ time to 50% of maximum IAsp concentration in the late part of the pharmacokinetic profile^a^For treatment comparison of faster aspart vs. IAsp

Total exposure (AUC~IAsp,0--*t*~) and *C*~max,IAsp~ were comparable between faster aspart and IAsp both for free IAsp (treatment ratios faster aspart/IAsp \[95% CI\] 1.00 \[0.97−1.03\], *p* = 0.962; and 1.04 \[0.99−1.09\], *p* = 0.092, respectively) and for total IAsp (1.01 \[0.97−1.04\], *p* = 0.760; and 1.04 \[0.99−1.08\], *p* = 0.101, respectively) (ESM Online Resource 1, Table S7).

Relationship Between Anti-IAsp Antibodies and the Measurement of Free Versus Total IAsp {#Sec11}
---------------------------------------------------------------------------------------

The relationship between the level of anti-IAsp antibodies and the ratio of measured exposure of free versus total IAsp is presented in Fig. [2](#Fig2){ref-type="fig"}. Independent of trial product (faster aspart or IAsp), there was a clear relation between the anti-IAsp antibody level and the ratio of free versus total IAsp for AUC~IAsp,0--*t*~ both in the clinical pharmacology trials and the phase IIIa trial. Thus, in subjects with low anti-IAsp antibody levels, AUC~IAsp,0--*t*~ for free IAsp was closer to AUC~IAsp,0--*t*~ for total IAsp. Conversely, in subjects with high anti-IAsp antibody levels, AUC~IAsp,0--*t*~ for free IAsp was small relative to AUC~IAsp,0--*t*~ for total IAsp.Fig. 2Relationship between anti-IAsp antibody level and the ratio of free versus total IAsp exposure in four pooled clinical pharmacology trials (**a**) and a phase IIIa trial (**b**) with faster aspart and IAsp. The horizontal dotted line represents similarity between free and total IAsp exposure. Results are based on 175 subjects in the pooled clinical pharmacology trials and 688 (faster aspart) and 352 (IAsp) subjects in the phase IIIa trial. *IAsp* insulin aspart, *%B/T* percent bound/total

Pharmacodynamics of Faster Aspart Versus IAsp in Relation to Anti-IAsp Antibody Level {#Sec12}
-------------------------------------------------------------------------------------

In the four quartiles of anti-IAsp antibody levels in the pooled analysis of clinical pharmacology trials, early glucose-lowering effect (AUC~GIR,0--60 min~) was greater with faster aspart than with IAsp and late glucose-lowering effect (AUC~GIR,2--*t*~) was smaller with faster aspart than with IAsp (Table [4](#Tab4){ref-type="table"}). Furthermore, there was essentially no relationship between the level of anti-IAsp antibodies and total glucose-lowering effect in a clamp setting (Fig. [3](#Fig3){ref-type="fig"}a) or between the level of anti-IAsp antibodies and 1-h postprandial glucose increment in a meal test (Fig. [3](#Fig3){ref-type="fig"}b).Table 4Early glucose-lowering effect and offset of glucose-lowering effect for faster aspart versus insulin aspart in subjects with type 1 diabetes mellitus with different anti-insulin aspart antibody levelsAnti-IAsp antibody quartilesAnti-IAsp antibody level at baseline (%B/T)AUC~GIR,0--60 min~ (mg/kg)AUC~GIR,2--*t*~ (mg/kg)Arithmetic meanMinimumMaximumFaster aspart (geometric mean)IAsp (geometric mean)Geometric mean treatment ratio (faster aspart/IAsp)Faster aspart (geometric mean)IAsp (geometric mean)Geometric mean treatment ratio (faster aspart/IAsp)Quartile 11.65− 0.113.11149.5112.31.33621.0738.40.84Quartile 24.863.126.53162.9112.91.44676.2744.70.91Quartile 310.466.6515.68149.0119.01.25746.2815.30.92Quartile 426.9415.8466.94165.8122.91.35718.2775.40.93Results are based on 112 subjects*AUC*~*GIR,0*--*60* *min*~ area under the curve for the glucose infusion rate from time zero to 60 min, *AUC*~*GIR,2*--*t*~ area under the curve for the glucose infusion rate from 2 h, *IAsp* insulin aspart,  *%B/T* percent bound/totalFig. 3Relationship between anti-IAsp antibody level and total glucose-lowering effect (AUC~GIR,0--*t*~) in three pooled clinical pharmacology trials (**a**) or ΔPPG~1 h~ in a phase IIIa trial (**b**) with faster aspart and IAsp. Results are based on 112 subjects in the pooled clinical pharmacology trials and 344 (faster aspart) and 348 (IAsp) subjects in the phase IIIa trial. Dotted lines are the estimated regression lines for faster aspart (blue) and IAsp (grey), respectively, including the coefficients of determination (*R*^2^) and the *p* values for a test of the slope being equal to zero (i.e. horizontal regression line). *AUC*~*GIR,0*--*t*~ total area under the curve for glucose infusion rate, *IAsp* insulin aspart,  *%B/T* percent bound/total, *ΔPPG*~*1* *h*~ 1-h postprandial plasma glucose increment

Discussion {#Sec13}
==========

The main finding of the present study was the consistently faster absorption, greater early exposure and earlier offset of exposure for faster aspart than IAsp when using either free or total IAsp to determine the pharmacokinetic properties in subjects with T1DM. Although the general exposure level for both insulin products was almost twice as high for total versus free IAsp, the onset of appearance, *t*~Early 50 % *C*max~ and *t*~max~ were remarkably similar for free and total IAsp. Moreover, the quantitative differences between faster aspart and IAsp for early exposure were in the same range for free and total IAsp, and the relative differences between faster aspart and IAsp for offset of exposure were comparable for the free and total IAsp assay method. It was evident from the present findings that the level of anti-IAsp antibodies could at least partly explain the different exposure level for free and total IAsp. The ratio of free/total IAsp for AUC~IAsp,0--*t*~ was shown to decrease with increasing anti-IAsp antibody levels (Fig. [2](#Fig2){ref-type="fig"}), which is in accordance with several previous observations with other insulins \[[@CR6], [@CR21]--[@CR23]\].

The consistency between pharmacokinetic results for free and total IAsp with respect to the relative comparison of faster aspart and IAsp may be due to the fact that the active drug substance is the same for both insulins, and therefore the same assay was used to assess pharmacokinetics for both insulin products. Importantly, the current findings cannot necessarily be extended to other insulin products. Thus, it cannot be inferred from the present study that a comparison of pharmacokinetic properties between two different insulins will always lead to similar conclusions irrespective of assaying free or total insulin. Therefore, it is important to obtain consensus on the preferred insulin assay method (free or total insulin), particularly when investigating previously insulin-treated subjects who potentially have developed anti-insulin antibodies. Interestingly, it appears that there is currently a lack of consistency within and between some regulatory authorities with respect to the preferred assay method for assessing exogenous insulin pharmacokinetic properties \[[@CR12], [@CR13], [@CR24]\].

There are several examples of hormones other than insulin that are present in the circulation in both a bound and a free fraction, e.g. thyroxine, testosterone, growth hormone and insulin-like growth factor-1 all circulate in the bloodstream bound to thyroid-binding globulin, sex hormone-binding globulin, growth hormone-binding protein and insulin-like growth factor-binding protein, respectively, in addition to their free fractions \[[@CR25]\]. For all these hormones as well as for insulin, it is hypothesised that their effects are proportional to the free hormone concentration in contrast to the total hormone concentration \[[@CR1], [@CR2], [@CR25]\]. This is important to bear in mind when assaying these hormones with the purpose of relating their pharmacokinetic properties to pharmacodynamic or effect measures.

A number of older studies have demonstrated altered insulin pharmacokinetics in subjects with higher versus lower anti-insulin antibody levels. The rise in insulin concentration shortly after dosing was delayed and the time to maximum concentration and the half-life were both extended in subjects with higher anti-insulin antibody levels \[[@CR3], [@CR26]\]. However, the clinical significance of these findings is unclear since several later studies have shown no effect of anti-insulin antibodies on the pharmacodynamic properties of insulin products \[[@CR23], [@CR27], [@CR28]\]. In accordance with the latter, the present study showed that early glucose-lowering effect within 60 min of dosing as well as late glucose-lowering effect from 2 h after dosing did not consistently change across the four quartiles of anti-IAsp antibody levels. Furthermore, total glucose-lowering effect appeared to be essentially unaffected by the level of anti-IAsp antibodies. Importantly, studies have shown that anti-insulin antibodies have no clinically significant impact on the efficacy or safety of various insulin products including inhaled insulin, which is known to elicit a greater anti-insulin antibody response than seen after subcutaneous insulin administration \[[@CR4], [@CR27], [@CR29]--[@CR31]\]. Thus, it seems reasonable to at least conclude that development of low-to-moderate levels of anti-insulin antibodies are of limited clinical relevance for patients with diabetes.

It has previously been shown that offset of exposure occurs earlier for faster aspart than for IAsp when pharmacokinetics were measured as free IAsp \[[@CR16]\]. In the current study, this finding was confirmed also when measuring total IAsp. A potential benefit of the earlier offset of faster aspart versus IAsp could be an improved match between meal glucose absorption and insulin exposure and effect in the late postprandial period. This, in turn, could reduce the risk of late postprandial hypoglycaemia resulting from an insulin effect that lasts longer than it takes to fully absorb glucose following a meal \[[@CR32]\]. Indeed, it was recently shown in an analysis of two phase III trials comparing faster aspart and IAsp in a basal-bolus regimen in subjects with T1DM that the rate of meal-related severe or blood glucose-confirmed hypoglycaemia in the period from 3 to 4 h post-meal was significantly lower for faster aspart than for IAsp in one of the trials \[[@CR33]\]. The same analysis also showed a significantly higher rate of hypoglycaemia for faster aspart than for IAsp in the period from 0 to 1 h post-meal in the other trial. These findings suggest that treatment differences between faster aspart and IAsp in the meal-related rate of hypoglycaemia may reflect the faster onset and offset of glucose-lowering effect for faster aspart than for IAsp \[[@CR33]\].

Strengths of the current investigation included the high number of subjects in the analyses, the wide span of demographics among the analysed population and the comparable designs of the clinical pharmacology trials, particularly regarding pharmacokinetic methodology and choice of comparator. It might be a limitation of the pooled analysis of clinical pharmacology trials that only a few subjects with moderate-to-high anti-IAsp antibody titres were included. In order to address this limitation, the effect of the anti-IAsp antibody level on the ratio of free/total IAsp for AUC~IAsp,0--*t*~ was investigated in a much larger group of subjects from a phase IIIa trial with faster aspart and IAsp. Based on the same phase IIIa trial, the relationship between anti-IAsp antibody levels and 1-h postprandial glucose increment during a meal test was investigated. In the phase IIIa trial, maximum observed anti-IAsp antibody titres were higher than in the clinical pharmacology trials (ESM Online Resource 1, Table S3) and a considerably greater number of subjects had moderate-to-high anti-IAsp antibody levels (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}). Both analyses confirmed the conclusions from the pooled clinical pharmacology analysis. Notably, the slightly increasing slopes of the estimated regression lines for faster aspart in Fig. [3](#Fig3){ref-type="fig"} indicate that, based on the clinical pharmacology trials, higher anti-IAsp antibody level would be associated with slightly greater glucose-lowering effect and, based on the phase IIIa trial, a higher anti-IAsp antibody level would be associated with slightly less glucose-lowering effect. Based on these findings combined with the very low coefficients of determination (*R*^2^), it should be reasonable to conclude that higher anti-IAsp antibody levels do not influence faster aspart or IAsp pharmacodynamics.

Another limitation of the present investigation was that it could not be directly estimated whether free or total IAsp is the best predictor of glucose-lowering effect. In the clinical pharmacology trials, each subject received only one dose level, and in the majority of trials this dose level was the same for all subjects (0.2 U/kg). Therefore, the range of exposure values within the population was too narrow to reliably investigate the pharmacokinetic/pharmacodynamic relationship. In the literature, the consensus is that circulating free insulin represents the biologically active pool and thus may be the best predictor of glucose-lowering effect \[[@CR1], [@CR2]\].

Conclusion {#Sec14}
==========

In a pooled analysis of four clinical pharmacology trials in subjects with T1DM, faster onset of appearance, greater early exposure and earlier offset of exposure were shown with faster aspart than with IAsp, both when using free and total IAsp to assess pharmacokinetics. Higher anti-IAsp antibody levels were associated with greater exposure for total than for free IAsp. However, the level of anti-IAsp antibodies did not appear to affect the overall glucose-lowering effect of faster aspart and IAsp or the greater early glucose-lowering effect and the smaller late glucose-lowering effect provided by faster aspart than by IAsp.
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